BARDA and the Janssen Pharmaceutical Companies of Johnson & Johnson expand Phase 2a COVID-19 vaccine trial to include adolescent population


WEB ANNOUNCEMENT
About Image

BARDA and Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen), are increasing ongoing efforts to develop an expanded indication for a vaccine to prevent COVID-19 in adolescents ages 12-17. BARDA is supporting additional development of Janssen’s COVID-19 investigational vaccine, Ad26.COV2.S, with expansion of a Phase 2a clinical trial for adolescents participating with their parents’ consent. The clinical trial is the next step in assessing the safety and efficacy of Ad26.COV2.S in volunteers 12-17 years of age. The trial is currently ongoing in the UK and Spain. Preparations for the clinical trial in the US and other countries are ongoing.

BARDA’s support for the Janssen COVID-19 Vaccine started in February 2020. In August 2020, BARDA, in collaboration with Department of Defense, expanded support to include a manufacturing demonstration project to manufacture and deliver 100 million doses of the company’s COVID-19 vaccine candidate. The Janssen COVID-19 Vaccine was authorized under Emergency Use Authorization for adults in the United States in February 2021.

The Company’s COVID-19 Vaccine leverages the AdVac® vaccine platform, a proprietary technology that was also used to develop and manufacture Janssen’s European Commission-approved Ebola vaccine regimen and construct its investigational Zika, RSV, and HIV vaccines.

This award is one component of BARDA’s COVID-19 medical countermeasure portfolio; visit BARDA’s COVID-19 Portfolio to learn more.

About Janssen:

The following information is provided by the company and does not indicate endorsement by the federal government of the company or its products.

Janssen, the Pharmaceutical Companies of Johnson & Johnson, is creating a future where disease is a thing of the past. The Company works tirelessly to make that future a reality for patients everywhere by fighting sickness with science, improving access with ingenuity, and healing hopelessness with heart. Janssen focuses on areas of medicine where it can make the biggest difference: Cardiovascular & Metabolism, Immunology, Infectious Diseases & Vaccines, Neuroscience, Oncology, and Pulmonary Hypertension.

Last Updated: April 02, 2021

COVID-19 Medical Countermeasure Portfolio

This award is one component of BARDA's expanding COVID-19 medical countermeasure portfolio; visit BARDA's COVID-19 Portfolio to learn more.

Website Refresh - www.medicalcountermeasures.gov is pleased to announce a phased launch of our newly redesigned public website. We are making website improvements to provide a more modern and customer-centric web experience. Over the next several months you will see differences throughout the site while we continue implementing updates. Thank you for your understanding and please let us know if you have any questions: techwatchinbox@hhs.gov